Description

Cartalax is a synthetic tripeptide composed of alanine, glutamic acid, and aspartic acid. Its structure enables interaction with cellular mechanisms in cartilage (chondrocytes) and bone-regulating thyroid cells. The peptide may support joint health by promoting collagen production—a key structural protein in connective tissues—and reducing programmed cell death (apoptosis) in stressed cartilage cells. Its effects stem from inhibiting enzymes like matrix metalloproteinases that break down cartilage, while simultaneously curbing inflammatory signaling molecules. Cartalax also appears to influence calcium metabolism through thyroid C cells, potentially aiding bone density.

Composition: 80 mg lyophilized blend per vial
50 mg GHK-Cu | 10 mg BPC-157 | 10 mg TB-500 | 10 mg KPV

Properties of Cartalax

Peptide Structure:

This content is provided strictly for research purposes and does not constitute an endorsement or recommendation for the non-laboratory application or improper handling of peptides designed for research. The information, including discussions about specific peptides and their researched benefits, is presented for informational purposes only and must not be construed as health, clinical, or legal guidance, nor an encouragement for non-research use in humans. Peptides described here are solely for use in structured scientific study by authorized individuals. We advise consulting with research experts, medical practitioners, or legal counsel prior to any decisions about obtaining or utilizing these peptides. The expectation of responsible, ethical utilization of this information for legitimate investigative and scholarly objectives is paramount. This notice is dynamic and governs all provided content on research peptides.